United Therapeutics (UTHR) Change in Receivables (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Change in Receivables data on file, last reported at -$38.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 189.46% year-over-year to -$38.2 million; the trailing twelve-month figure through Mar 2026 stood at -$10.0 million (down 167.57% YoY), and the FY2025 full-year result was $70.9 million, up 17625.0% from the prior year.
• Change in Receivables slipped to -$38.2 million in Q1 2026, from $52.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $138.1 million in Q2 2023 to a low of -$85.9 million in Q1 2023.
• A 5-year average of $6.7 million and a median of $2.8 million in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables jumped 4832.14% in 2023 and sank 407.88% in 2024, its largest moves.
• Tracing UTHR's Change in Receivables over 5 years: stood at -$11.3 million in 2022, then jumped by 279.65% to $20.3 million in 2023, then slumped by 407.88% to -$62.5 million in 2024, then soared by 184.0% to $52.5 million in 2025, then slumped by 172.76% to -$38.2 million in 2026.
• Business Quant data shows UTHR's Change in Receivables at -$38.2 million in Q1 2026, $52.5 million in Q4 2025, and -$81.6 million in Q3 2025.